DCVNM COVID-19 Committee: updates

2nd TC with members and observers
29th June 2020 12 pm CET
Manufacturers Alliance for Global Equitable Access to Coronavirus Vaccines (MANAGE-COV) Summit

The meeting will start momentarily
COVID-19 - Financing Structures for Vaccine Manufacturing

COVAX Facility can be complemented through an IFC-led financing and technical assistance platform to lever grant funding in scaling up manufacturing

**COVAX “Push Financing” Mechanisms**

- Funding for R&D
- Renumeration for Technology and IP Transfer

**Vaccine Developers**
- Formulations provided to eligible manufacturers

**Financing Facility**
- Contingent Advance Purchase Agreements
- Working Capital and CAPEX Financing

**Technical Assistance Facility**
- Partial Guarantees or concessional funding for blending
- Funding for TA
- TA for Quality, Repurposing, Supply Chain Management

**Donors and Partners**

**Company A**

**Company B**

**Company C**

... **Company N**

**Fair Allocation Mechanism**
ACT-ACCELERATOR
Total investment needed
US$ 31.3 BILLION

Vaccines

CEPI
Gavi

$18.1 BILLION
Needed for next 18 months

2 billion
doses globally by the end of 2021

Therapeutics

Unitaid

$7.2 BILLION
Needed for next 12 months

245 million
therapeutics courses in Low and Middle-Income Countries by mid-2021

Diagnostics

FIND

$6 BILLION
Needed for next 12 months

500 million
tests in Low and Middle-Income Countries by mid-2021

The ACT-Accelerator will deliver new tools for the whole world.

Health Systems Connector

The World Bank

Required investments

A total of US$31.3 billion is needed for the work of the ACT Diagnostics, Therapeutics and Vaccines pillars. These needs have been developed through pillar-specific scenarios and assumptions that are detailed in their respective plans and investment cases. The total needs have been calculated over a 12 months period for the Therapeutics and Diagnostics pillars, and 18 months for the Vaccines pillar.

ACT-Accelerator needs (over the next 12 months for Diagnostics and Therapeutics and 18 months for Vaccines)

Phase 1
Immediate need: US$17.1 billion

Phase 2
Total need: US$31.3 billion

The ‘immediate needs’ represent the critical investments required within the next six months to meet the ACT-Accelerator targets. These needs can be broken down into the major activities of each pillar as follows:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Immediate Needs</th>
<th>Total Needs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccines R&amp;D</td>
<td>$1.58 billion</td>
<td>$2.48 billion</td>
</tr>
<tr>
<td>Vaccines Market Prep. &amp; Manufacturing</td>
<td>$6.48 billion</td>
<td>$7.08 billion</td>
</tr>
<tr>
<td>Vaccines Procurement &amp; Delivery</td>
<td>$3.48 billion</td>
<td>$8.78 billion</td>
</tr>
<tr>
<td>Therapeutics R&amp;D</td>
<td>$1.08 billion</td>
<td>$2.08 billion</td>
</tr>
<tr>
<td>Therapeutics Market Prep. &amp; Manufacturing</td>
<td>$0.38 billion</td>
<td>$0.88 billion</td>
</tr>
<tr>
<td>Therapeutics Procurement &amp; Delivery</td>
<td>$2.58 billion</td>
<td>$4.68 billion</td>
</tr>
<tr>
<td>Diagnostics R&amp;D</td>
<td>$0.38 billion</td>
<td>$0.38 billion</td>
</tr>
<tr>
<td>Diagnostics Market Prep. &amp; Manufacturing</td>
<td>$0.48 billion</td>
<td>$0.78 billion</td>
</tr>
<tr>
<td>Diagnostics Procurement &amp; Delivery</td>
<td>$1.38 billion</td>
<td>$5.08 billion</td>
</tr>
</tbody>
</table>

NOTE: assuming safe and effective vaccines are developed in the near future, ACT’s current estimate for the delivery of 2 billion doses of vaccine by the end of 2021 is up to US$18.1 billion, with 950 million of those doses procured by self-financing high and upper middle-income countries through the COVAX Facility. These numbers will be updated as understanding of the technology that the successful vaccine candidates will be based on, and the number of doses required to protect people from COVID-19, improves.

26 June 2020

https://www.who.int/publications/m/item/act-accelerator-investment-case
These generous pledges represent 11% of the total investment needed for ACT Diagnostics, Therapeutics and Vaccines:

<table>
<thead>
<tr>
<th></th>
<th>Proportion funded</th>
<th>Immediate needs</th>
<th>Total needs</th>
<th>% of total need pledged</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vaccines</strong></td>
<td>$2.6Bn</td>
<td>$11.3Bn</td>
<td>$18.1Bn</td>
<td>14%</td>
</tr>
<tr>
<td><strong>Therapeutics</strong></td>
<td>$0.7Bn</td>
<td>$3.8Bn</td>
<td>$7.2Bn</td>
<td>10%</td>
</tr>
<tr>
<td><strong>Diagnostics</strong></td>
<td>$0.1Bn</td>
<td>$2.0Bn</td>
<td>$6.0Bn</td>
<td>2%</td>
</tr>
</tbody>
</table>

In summary, the diagnostic, therapeutic and vaccine pillars of the ACT-Accelerator will need an additional US$27.9 billion, including US$13.7 billion to cover immediate needs (i.e. $17.1 B required - $3.4 B pledged). Fortunately, there is growing recognition of the benefits of collaborating through ACT, our most promising hope of a successful global effort to end the virus.
Saturday afternoon the European Commission led Global Goal: Unite for our Future Summit again brought together a tremendous line-up of world leaders in support of the ACT Accelerator and the COVID Response.

The Summit mobilized US$1.5 billion in new cash grants and US$5.4 billion in new loans & guarantees,

totalling US$6.9 billion in new funding.
CEPI query to DCVMN nomination of at least two representatives to the COVAX technical working group

- DCVMN Covid committee Chairperson, Adriansjah Azhari, (viral vaccines large-scale manufacturing expertise)
